CD8A and neoplasm: While both CD4+ and CD8+ T cells are activated by the treatment, only CD8+ T cells are required to achieve TA-expressing cancer cell clearance, confirming that, when TA and cytokines are co-delivered, robust anti-tumor immunity is achieved independently of CD4+ T cell help.